FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4660092> ?p ?o ?g. }

• W4660092 abstract "Joseph P McEvoy, MD1; Daniel Zigman, MD2; Howard C Margolese, MD, CM, MSc, FRCPC3 Can J Psychiatry. 2010;55(3):144-149. Are SGAs Better Than FGAs? No The FGAs are a group of drugs with the common pharmacological action of D2 blockade. D2 blockade offers impressive (relative to placebo) but limited therapeutic benefit in the treatment of acute psychotic exacerbations and in the prevention of psychotic relapse. Most patients have incomplete relief of psychopathology.1 However, the FGAs are a pharmacologically disparate group, ranging from relatively clean D2 blocking agents (for example, perphenazine) to agents with multiple additional pharmacological actions (for example, thioridazine) that underwrite an array of unnecessary side effects. One might surmise that an FGA that produced severe anticholinergic toxicities, distressing autonomic side effects (for example, sexual dysfunction and orthostatic hypotension), and disproportionate prolactin elevations would have been rarely prescribed. In fact, thioridazine was the most widely prescribed FGA in the United States for a time; it was sedating and had fewer propensities for EPSEs. It was widely used for children who, when taking it, could review the same schoolwork over and over again and experience each page's content as new and exciting each time they read it. It was also widely used in the elderly (for example, someone my age) in whom cholinergic neurons are disappearing at alarming rates. And so it goes. The only useful thing that FGAs do is block D2 receptors. When about 60% to 70% D2 blockade is achieved, mesolimbic dopamine-releasing neurons begin a transition into depolarization block, a process that underlies therapeutic recovery. The induction of this process is a yes or no phenomenon, not a graded phenomenon, an on-off switch rather than a rheostat. More pressure on the switch (that is, higher doses) does not hasten the process or intensify it.1 However, clinicians treated an FGA dose as a rheostat, a throttle, a gas pedal (despite study after study proving the incorrectness of this approach) in futile efforts to obtain more therapeutic benefit than the FGAs had to offer, and accepted unnecessary coarse EPSE. They added anticholinergic drugs to hide these EPSE, accepting unnecessary dry mouth, blurred vision, constipation, and memory impairment, and leaving patients at high risk for TD. To use FGAs well, clinicians must tailor doses to the achievement of 60% to 70% D2 blockade. This can be done grandly with positron emission tomography scanning or hormone challenge procedures. Or, this can be done humbly by examining patients for muscle tone and fluidity of movement prior to starting an FGA, and then repeating this examination as dose is slowly increased. The examination takes less than 2 minutes. When a slight increase in bradykinesia-rigidity is induced, 60% to 70% D2 blockade has been achieved. As much therapeutic response as an individual patient will garner from an FGA will unfold over the next few weeks. Higher doses bring coarse EPSE and do not hasten or enhance therapeutic response.2 If therapeutic response is inadequate, a different approach (for example, clozapine), not higher doses, is needed. Consider if clinicians treated every patient with epilepsy with diphenylhydantoin 300 mg daily, many patients would do well, some would have inadequate brain levels and unnecessary seizures, and some would have toxic ataxias. If these same clinicians instead repeatedly examined patients and adjusted diphenylhydantoin doses upward or downward to the appearance of mild nystagmus or ataxia, more patients would do well and few if any would be under- or overdosed. If clinicians treated every patient with psychosis with an FGA at doses that produced mild bradykinesia-rigidity (instead of at some standard dose), more would do well and few if any would be under- or overdosed. Unfortunately, the use of such a fundamental pharmacological principle never became routine practice among clinicians prescribing FGAs. …" @default.
• W4660092 created "2016-06-24" @default.
• W4660092 creator A5053602165 @default.
• W4660092 creator A5066940389 @default.
• W4660092 creator A5082093233 @default.
• W4660092 date "2010-03-01" @default.
• W4660092 modified "2023-09-26" @default.
• W4660092 title "First- and Second-Generation Antipsychotics" @default.
• W4660092 cites W1983063140 @default.
• W4660092 cites W2005697734 @default.
• W4660092 cites W2009052798 @default.
• W4660092 cites W2013791308 @default.
• W4660092 cites W2028521379 @default.
• W4660092 cites W2038114663 @default.
• W4660092 cites W2044337871 @default.
• W4660092 cites W2047069677 @default.
• W4660092 cites W2064580795 @default.
• W4660092 cites W2070427088 @default.
• W4660092 cites W2078366085 @default.
• W4660092 cites W2080648851 @default.
• W4660092 cites W2081978467 @default.
• W4660092 cites W2096635847 @default.
• W4660092 cites W2097116748 @default.
• W4660092 cites W2109196233 @default.
• W4660092 cites W2111883919 @default.
• W4660092 cites W2130848936 @default.
• W4660092 cites W2145065685 @default.
• W4660092 cites W2145240519 @default.
• W4660092 cites W2152770536 @default.
• W4660092 cites W2156730504 @default.
• W4660092 cites W2159155203 @default.
• W4660092 cites W2166765859 @default.
• W4660092 cites W2170562380 @default.
• W4660092 cites W2171958702 @default.
• W4660092 cites W4232804908 @default.
• W4660092 cites W4253251124 @default.
• W4660092 doi "https://doi.org/10.1177/070674371005500305" @default.
• W4660092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20370964" @default.
• W4660092 hasPublicationYear "2010" @default.
• W4660092 type Work @default.
• W4660092 sameAs 4660092 @default.
• W4660092 citedByCount "3" @default.
• W4660092 countsByYear W46600922012 @default.
• W4660092 countsByYear W46600922013 @default.
• W4660092 countsByYear W46600922014 @default.
• W4660092 crossrefType "journal-article" @default.
• W4660092 hasAuthorship W4660092A5053602165 @default.
• W4660092 hasAuthorship W4660092A5066940389 @default.
• W4660092 hasAuthorship W4660092A5082093233 @default.
• W4660092 hasConcept C118552586 @default.
• W4660092 hasConcept C126322002 @default.
• W4660092 hasConcept C15744967 @default.
• W4660092 hasConcept C169760540 @default.
• W4660092 hasConcept C170493617 @default.
• W4660092 hasConcept C2776412080 @default.
• W4660092 hasConcept C2778468042 @default.
• W4660092 hasConcept C2778689640 @default.
• W4660092 hasConcept C2778775820 @default.
• W4660092 hasConcept C2780494398 @default.
• W4660092 hasConcept C2780688371 @default.
• W4660092 hasConcept C2910745098 @default.
• W4660092 hasConcept C42219234 @default.
• W4660092 hasConcept C44208683 @default.
• W4660092 hasConcept C513476851 @default.
• W4660092 hasConcept C71924100 @default.
• W4660092 hasConcept C98274493 @default.
• W4660092 hasConceptScore W4660092C118552586 @default.
• W4660092 hasConceptScore W4660092C126322002 @default.
• W4660092 hasConceptScore W4660092C15744967 @default.
• W4660092 hasConceptScore W4660092C169760540 @default.
• W4660092 hasConceptScore W4660092C170493617 @default.
• W4660092 hasConceptScore W4660092C2776412080 @default.
• W4660092 hasConceptScore W4660092C2778468042 @default.
• W4660092 hasConceptScore W4660092C2778689640 @default.
• W4660092 hasConceptScore W4660092C2778775820 @default.
• W4660092 hasConceptScore W4660092C2780494398 @default.
• W4660092 hasConceptScore W4660092C2780688371 @default.
• W4660092 hasConceptScore W4660092C2910745098 @default.
• W4660092 hasConceptScore W4660092C42219234 @default.
• W4660092 hasConceptScore W4660092C44208683 @default.
• W4660092 hasConceptScore W4660092C513476851 @default.
• W4660092 hasConceptScore W4660092C71924100 @default.
• W4660092 hasConceptScore W4660092C98274493 @default.
• W4660092 hasLocation W46600921 @default.
• W4660092 hasLocation W46600922 @default.
• W4660092 hasOpenAccess W4660092 @default.
• W4660092 hasPrimaryLocation W46600921 @default.
• W4660092 hasRelatedWork W125429244 @default.
• W4660092 hasRelatedWork W150982889 @default.
• W4660092 hasRelatedWork W1523035636 @default.
• W4660092 hasRelatedWork W168625158 @default.
• W4660092 hasRelatedWork W1900388131 @default.
• W4660092 hasRelatedWork W1993952982 @default.
• W4660092 hasRelatedWork W2043296178 @default.
• W4660092 hasRelatedWork W2058725970 @default.
• W4660092 hasRelatedWork W206597414 @default.
• W4660092 hasRelatedWork W2083864791 @default.
• W4660092 hasRelatedWork W2116211972 @default.
• W4660092 hasRelatedWork W2167019218 @default.
• W4660092 hasRelatedWork W2290974733 @default.

• next